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Van Acker et al.
(1) reported the presence of macro-LDH in serum 10 days after administration of streptokinase in the very acute phase of an acute myocardial infarction (AM!). They claimed a causal relationship between the finding of macro-LDH and administered streptokinase. However, a relationship with AM! itself, or its underlying cause, is not to be excluded. 14 ± 3.9
1.7 ± 0.5 4.9 ± 1.0 100 ± 24 Surveying our own series, we found It has been consistently reported that concentrations of angiotensin-convertingenzyme (ACE; EC 3.4.15.1) are increased in patients with hyperthyroidism. Furthermore, except in dofined patient groups, measurements of free thyroid hormones (free triiodothyronine and free thyroxin, fT3 + fT4) are well reflected by the measurement oftotal thyroid hormones (tT + tT4) in both normal subjects and those with thyroid dysfunction.
It is, therefore, difficult to explain the findings of Kuyl and Van Der Walt (Clin Chem 1986; 32:1595) , who reported that, in a mixed group of hyperthyroid, euthyreid, and hypothyroid patients, ACE was significantly related only to f T3. It is highly unlikely that in their group of approximately 100 subjects a large proportion had a T3 toxicosis that could dissociate the f T3 relationship with other thyroid hormones and with ACE. Unfortunately, the means of categonration of the subjects' thyroid status were not stated. The absence ofa correlation between any thyroid hormone and ACE in their second group of virt.uaily all euthyroid subjects is not sur- Our data show a consistent, statistically significant correlation between concentrations of ACE and thyroid hormones, yielding similar values whether tT4, fT4, tT3, or fT3 is used as the correlate with ACE (n = 61, r = 0.62, 0.61, 0.65, or 0.61 respectively; P <0.001). Our data are consistent with the increase of ACE in hyperthyroidism, and with the close correlation between T4 and T3 and between bound and free fractions ofthe thyroid hormones.
The reasons for the increased activities ofACE in hyperthyroidism are not known, nor do Kuyl and Van Der Walt's data address that question. However, Czernobilsky et al. (Klin Wochenschr 1985; 63:518) have shown that ACE activities are indreased to a similar extent in Graves' disease and toxic nodular goiter (conditions that do not appear to have a common etiology); therefore, increased cellular immune activity may not provide a complete explanation for the ACE response in all hyperthyroid conditions. We investigated ACE release by damaged tissues in groups of clinically defined patients and failed to show either an increase in ACE activity in plasma or a correlation between ACE and biochemical markers of tissue damage (e.g., creatine kinase in patients with myocardial infarction). This does not support the idea of "tissue leakage." Furthermore, in rats treated with thyroid hormones, we demonstrated increased ACE activity in lung without a corresponding increase in plasma, in contradiction to the hypothesis of Yotsumoto (Ann Intern Med 1982; 96:326) that the increase of ACE in plasma in hyperthyroidism is due to nonspecific protesee activity, which increases cleavage of ACE from the lung endothelia (such a hypothesis would predict an increase in plasma ACE with a concomitant decrease in lung ACE). We have stimulated synthesis and secretion of ACE directly, however, by adding T3 (100 jnnol/L) to cultured aortic endothelial cells, suggesting that, in hyperthyroidism, the increase in ACE activity may be due to a direct effect at the cellular level (J R Soc Med 1987, in press ). This finding is consistent with the clinical studies of Smallridge et al. (J Am Med Assoc 1983; 250:2489) , who demonstrated an increase in plasma ACE in hypothyroid patients after T4 therapy. This increase has recently been shown by Cow et al. (J Clin Endocrinol Metab 1987; 64:364) to be dose-dependent.
